The aim of this paper is to specify the cost of treatment and care for people with Alzheimer's disease (AD) in the Czech Republic and also with a view to the future. Data availability is evaluated as well as the quality of cost comparison with other developed countries. Data for the Czech Republic will include data from the health insurance company regarding medicines and treatment, as well as a selected home caring for people with dementia and, ultimately, the Social Security Administration. The basic methods include an analysis of data from publicly available sources, direct interviews with the representatives of nursing homes caring for people with dementia and the representative of the Social Security Administration of the Czech Republic. Items will be specified within the category of direct costs. For the study, the indirect costs related to the loss of patient as well as caring person productivity are not considered. Costs for treatment and care are based from the data on 4162 patients, the costs of a bed from data on 391 beds in homes for the elderly. The average annual cost per patient with AD in the Czech Republic was calculated and came to the amount of 12,783 EUR. These items include outpatient care, inpatient care in a medical facility, inpatient care in homes and medications. In terms of share of these items on the direct costs, the largest item are services provided by special homes which contributes to the direct costs by 94 %, medications create 1 % and treatment (both outpatient and inpatient) 5 %. In the case of home care the total costs are lower at 4698 EUR. The Czech Republic as well as other developed countries are faced with the problem of unified accounting cost of people suffering from Alzheimer's disease. This then causes the calculation of the economic burden to be very difficult and indicative values.

Department of Economy Faculty of Informatics and Management University of Hradec Kralove Rokitanskeho 62 50003 Hradec Kralove Czech Republic

Neurol Sci. 2017 May;38(5):923-924. doi: 10.1007/s10072-017-2840-x. PubMed

See more in PubMed

Int Psychogeriatr. 2007 Aug;19(4):705-18 PubMed

Value Health. 2011 Sep-Oct;14(6):827-35 PubMed

J Alzheimers Dis. 2008 Sep;15(1):109-15 PubMed

Neuropsychiatr Dis Treat. 2015 Sep 11;11:2349-54 PubMed

Health Aff (Millwood). 1993 Summer;12(2):164-76 PubMed

Alzheimers Dement. 2015 Aug;11(8):933-45 PubMed

Curr Alzheimer Res. 2015;12(9):903-11 PubMed

Gerontologist. 2003 Apr;43(2):158-64 PubMed

Int J Geriatr Psychiatry. 2006 Oct;21(10):972-6 PubMed

Curr Alzheimer Res. 2010 Jun;7(4):358-67 PubMed

Drugs Aging. 2004;21(5):279-95 PubMed

Health Policy. 2014 May;116(1):114-22 PubMed

Pharmacoeconomics. 2001;19(3):303-18 PubMed

Predictions of Alzheimer's disease treatment and care costs in European countries

The direct costs of multiple sclerosis-study in the Czech Republic

India must focus on the less explored Alzheimer's disease